Abstract: An actuated glove orthosis comprises a plurality of digits, each digit configured to be coupled to a finger, each digit defining at least one mechanical stop for preventing hyperextension. The orthosis may further comprise at least one actuator, and a plurality of cables, each cable coupled between a digit and the actuator. Activation of the actuator may increase tension on the plurality of cables to extend the plurality of digits. The device is entirely portable and leaves the hand free to grasp real objects, including as part of a standard therapy session.

Abstract: A body-weight support system is disclosed, including an improved body weight support apparatus and method. The system enables not only the support of patients undergoing rehabilitation therapies, but exercise modes that are both customizable and dynamic in nature, including alternative functionality at differing locations.

Abstract: A motorcycle seat-massage system includes a frame forming at least a front seat and a front backrest. The front backrest frame includes an upper lateral member. A first massage unit is disposed on the front backrest frame lateral member and is laterally translatable thereon. The massage unit includes an electric motor coupled to a drive unit for powered translation of the massage unit on the backrest frame lateral member and further includes a massage head having a plurality of spherical massagers affixed thereto. The massage head is rotationally coupled to the electric motor, and a flexible seat cover is fitted over the frame and the massage unit. At least one controller is electrically communicative with the massage unit, the controller is operable to selectively engage and disengage the massage unit.

Abstract: The vibration capsule has a movement generation unit, a movement control unit, a wireless communication unit and a power supply. The movement control unit provides instructions to the movement generation unit, which generates movements in configurable frequencies and duty cycles. The power supply unit provides power to the movement generation unit through movement control unit, which also decides work period and rest period for the capsule device. The vibration capsule device further includes a capsule movement detection unit, which includes at least one sensor unit and provides information to the wireless communication unit.

Abstract: A system includes a guidance device that provides feedback to a user to compress a patient's chest at a rate of between about 90 and 110 compressions per minute and at a depth of between about 4.5 centimeters to about 6 centimeters. The system includes a pressure regulation system having a pressure-responsive valve that is configured to be coupled to a patient's airway. The pressure-responsive valve is configured to remain closed during successive chest compressions in order to permit removal at least about 200 ml from the lungs in order to lower intracranial pressure to improve survival with favorable neurological function. The pressure-responsive valve is configured to remain closed until the negative pressure within the patient's airway reaches about ?7 cm H2O, at which time the pressure-responsive valve is configured to open to provide respiratory gases to flow to the lungs through the pressure-responsive valve.

Abstract: A pulmonary expansion therapy (PXT) device may be a handheld device that covers specific lung fields and may generate negative pressure fields locally. The device also may provide percussion therapy for airway clearance. The PXT may generate a localized negative pressure field non-invasively to the exterior of the chest wall, thereby increasing the functional residual capacity in underlying lung fields. As a result, increased ventilation and perfusion to the targeted internal lung field may be achieved by creating a decrease in the external barometric pressure relative to the more positive intrinsic airway pressures. The PXT device also may improve lung compliance by enabling a medical professional such as a Respiratory Therapist/Care provider to grab and elevate the chest wall to compensate for the dysfunction of the respiratory musculature responsible for lifting the chest wall during normal breathing.

Abstract: An illuminated foot spa is provided. The foot spa has a surface which defines a basin for containing water and a pump magnetically driven by rotating magnets. A mount defines part of the surface and holds the pump against rotation. A coil associated with the mount and disposed exteriorly of the surface of the basin and interiorly of a magnetic field produced by the rotating magnets to produce a current in the coil that powers a plurality of lights operatively connected to the coil. The light conductivity associated with the mount permits the plurality of lights to be visible interiorly of the basin.

Abstract: A single unit precast concrete tub (1) formed out of concrete wherein a plumbing system (10) and electrical system (11) are encased within preformed concrete walls. The fully encased plumbing system protects the pipes against damage and frost. Support brackets (15) are formed on an exterior surface (4) of the side wall (2) to provide attachment points for hoisting the precast tub for transportation and installation. The support brackets also provide attachment points for building auxiliary structures, such as decks, around the precast tub.

Abstract: Disclosed is a multi-functional electro-spoon needle therapeutic apparatus, which includes a top cover, locating pieces, a fixed lid, a rear cover, electro-spoon needles and an adjustment mechanism, wherein the locating pieces are respectively mounted on the top cover and the rear cover, and each locating piece is provided with a long groove; the fixed lid is respectively fixed on the top cover and the rear cover so as to respectively hold the locating pieces between the top cover and the fixed lid and between the rear cover and the fixed lid; the rear cover is arranged behind the top cover and connected to the top cover via the adjustment mechanism; and the electro-spoon needles are mounted in the long grooves of the locating pieces and can move along the long grooves. The apparatus has a simple structure, so a patient can perform acupuncture by himself.

Abstract: A biological sample containment system that includes a biological specimen collection container for collecting a biological sample and a label for the container is disclosed. In one embodiment, the label includes a first or front side and a second or rear side having a readable information portion. The label is affixable to the container by the second side and with the label affixed to the container, the readable information portion on the second side is readable through a portion of the container. By including readable information on the second or rear side of the label, the amount of readable information that can be included on the label is increased by using the previously unused rear side of the label.

Abstract: A medical solution packaging assembly comprising a medical solution container that houses a medical solution comprising a semi-permeable material including one or more surface that is at least partially permeable to air molecules and has low permeability to vapor molecules of the medical solution, wherein the medical solution container is configured to inflate beyond its original volume. The assembly further comprising a packaging comprising one or more surface within which the solution container resides; a compressing mechanism configured to apply external force onto at least one surface of the medical solution container or limit the volume to which the medical solution container inflates, wherein a volume of air ingress from an external environment of the medical solution container is less than that which would occur without the compressing mechanism.

Abstract: A bottle connector for use in a medical fluid transfer arrangement, the bottle connector having an axial direction and a radial direction and comprising a first part and a second part, the first part comprising a hollow piercing member comprising an inner gas channel and extending in the axial direction beyond the end of the first part. The second part comprises a bottle coupling member, for coupling the bottle connector to a medical bottle. The first and second parts are pre-connected and are concentrically arranged with respect to each other and the bottle connector has a transport configuration with a first, maximum length in which the piercing member is completely located within the bottle connector, and a fluid transfer configuration with a second, minimum length.

Abstract: A root canal filling cone made of a material having a composition that can maintain its physical and chemical characteristics and shelf life after sterilization, and a process of sterilizing the point/cone prior to shipment to a user. In one aspect, the cone is made of a composition that includes a plurality of base polymers of substantially equal amounts, and nanoparticles, which can withstand sterilization by gamma irradiation. In one embodiment, the compound includes Gutta Percha based polymers. In another aspect, the Gutta Percha based cone is packaged and sterilized by irradiation prior to shipment to a user. In one embodiment of the present invention, the irradiation is gamma irradiation.

Abstract: Dental compositions are disclosed. A dental composition can include a reaction produce of a reaction mixture comprising a first mixture and a second mixture. The first mixture can include a ceramic based biomaterial, and the second mixture can include mineral trioxide aggregate and a phosphoric acid monomer.

Abstract: The present invention provides a dental adhesive material kit excellent in storage stability of the materials and exhibiting excellent bond durability to dentin by photopolymerization. The present invention is a dental adhesive material kit comprising a dental aqueous adhesive composition (A) and a dental curable composition (B), wherein: the dental aqueous adhesive composition (A) comprises a (meth)acrylic polymerizable monomer (a) containing an acid group, a vanadium compound (b), water (c), a (meth)acrylic polymerizable monomer (d) containing an amino group, and a polymerization inhibitor (i); the content of the polymerization inhibitor (i) is 25 to 1000 parts by weight per 100 parts by weight of the vanadium compound (b); and the dental curable composition (B) comprises a (meth)acrylic polymerizable monomer (e) containing no acid group, a hydroperoxide (f), a photopolymerization initiator (g), and a filler (h) and does not comprise a thiourea compound.

Abstract: The present disclosure relates to a two-part cosmetic composition for changing color of keratinic fibers, comprising (a) a gel-like part containing optionally an oxidative dye precursor, and a thickener selected from the group of xanthan gum, anionic amphiphilic polymer, and combination thereof, and (b) an oxidizing part containing an oxidizing agent, and a thickener including one or more anionic amphiphilic polymers.

Abstract: A hair coloring mixture including a carrier liquid with alumino-silicate micro-tubes having a hair dye agent loaded into the lumen of the micro-tubes. The micro-tubes may be present in the carrier liquid in a concentration of between about 5 mg/ml and about 50 mg/ml, while the mixture will have a pH of between about 4 and about 7.

Abstract: A skin engaging shaving aid member suitable for use in a shaving device, said skin engaging shaving aid member comprising a thermally resilient sensate such as N-substituted menthanecarboxamide.

Abstract: A hair dye composition comprising the following components (A) and (B), in which the mass ratio of the component (B) to the component (A), (B)/(A), in a whole composition is 1 or more and 100 or less and the pH (25° C.) during application is 7.5 to 12: (A): one or more azo dyes selected from the group consisting of the following (A-1), (A-2) and (A-3): (B): at least one member selected from the group consisting of guanidine carbonate, guanidine hydrogen carbonate, sodium carbonate, sodium hydrogen carbonate, potassium carbonate, potassium hydrogen carbonate and lithium carbonate.

Abstract: This invention relates to the cosmetic use of at least one glycoside chosen from glycosides having the following general formula (I): Sacc-(CH2)i—X—R in order to increase the hair mass.

Abstract: The present disclosure relates to skincare products for treating the aging related issues of wrinkles or accidents such as scarring or burning and more specifically to specific formulations used to improve user outcomes in regards to skin elasticity, appearance and/or hydration. The contemplated products relate to formulations including combinations of biomimetic peptides and proteins of naturally occurring venoms in various known wildlife including bees, wasps, snakes, or snails, in a single formulation or in combination with various plant related ingredients with various carrier and/or medicament ability.

Abstract: Provided herein is a peptide, a cosmetic composition comprising the same, and a method for inhibiting skin-aging or skin-wrinkle formation using the same, the peptide having activities for facilitating the bindings between keratinocytes; and increasing the expressions of junction proteins.

Abstract: The present invention relates to the cosmetic use of a combination of a hydrolysed rice extract and a grapeseed extract as an active agent to protect cutaneous cells from pollution. The present invention relates also to a cosmetic method of treatment for protecting skin epidermal cells from atmospheric pollution comprising applying on the skin area to be treated a composition comprising a combination of a hydrolysed rice extract and a grapeseed extract.

Abstract: The present disclosure describes compositions and methods to promote wound healing. The compositions and methods include an interleukin-1 beta (IL-1B) receptor antagonist (IL-1Ra), such as anakinra.

Abstract: The composition containing a pamoate salt of donepezil, the method of preparation and the use thereof are disclosed.

Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

Abstract: An avian tincture composition and associated methods for producing the same for treatment of the avian species with the avian tincture. The avian tincture may be used in the treatment of abscesses, inflamed and swollen leg joints, respiratory issues, wounds, infection, and acute disease or parasite overload conditions.

Abstract: Discrete microstructures of predefined size and shape are prepared using sol-gel phase-reversible hydrogel templates. An aqueous solution of hydrogel-forming material is covered onto a microfabricated silicon wafer master template having predefined microfeatures, such as pillars. A hydrogel template is formed, usually by lowering the temperature, and the formed hydrogel template is peeled away from the silicon master template. The wells of predefined size and shape on the hydrogel template are filled with a solution or a paste of a water-insoluble polymer, and the solvent is removed to form solid structures. The formed microstructures are released from the hydrogel template by simply melting the hydrogel template in water. The microstructures are collected by centrifugation. The microstructures fabricated by this method exhibit pre-defined size and shape that exactly correspond to the microwells of the hydrogel template.

Abstract: The present invention relates to a pharmaceutical composition, particularly a modified release tablet composition comprising mirabegron or a pharmaceutically acceptable salt thereof and to a process for preparing such a composition.

Abstract: The present disclosure relates generally to rapid-release pharmaceutical dosage unit tablets containing a drug that is an inhibitor of the mitogen-activated protein kinase enzyme, a filler and a disintegrant, and to processes for forming the tablets. More specifically, the present disclosure relates to pharmaceutical dosage unit tablets containing cobimetinib, a least one filler, at least one lubricant and at least one disintegrant, and to methods for preparing the tablets from granules formed by dry granulation.

Abstract: The invention relates to methods for encapsulating a material comprising the steps of: (a) providing an aqueous solution or suspension of the material that is to be encapsulated, (b) warming the aqueous solution or suspension to a temperature that is sufficient to enable dissolution of a first biocompatible polymer in the aqueous solution or suspension without adversely affecting the properties of the material to be encapsulated, (c) dissolving the first biocompatible polymer in the aqueous solution or suspension, (d) de-aerating the solution or suspension obtained in step (c), (e) emulsifying the solution or suspension obtained in (d) in a biocompatible oil comprising a surfactant to create microdroplets, and (f) hardening the microdroplets by dropwise addition of an aqueous solution comprising Zn2+ ions and a second biocompatible polymer to form microcapsules; the invention further relates to microcapsules obtained by methods of the invention and their uses.

Abstract: A nanoparticle having a solid core comprising a biologically active substance, said core being enclosed by an inorganic coating, a method for preparing the nanoparticle, and the use of the nanoparticle in therapy. A kit comprising the nanoparticle and a pharmaceutical composition comprising the nanoparticle.

Abstract: A device for delivery of a therapeutic agent to a surgical cavity, including: a porous, mucoadhesive, freeze-dried polymeric matrix having first and second opposed surfaces, the matrix formed by a composition including chitosan; a plurality of particles embedded within the matrix, the particles containing the therapeutic agent and having a coating around the therapeutic agent, the coating including chitosan; and an additive selected from the group consisting of a hydration promoter, a particle adhesion inhibitor, a particle aggregation inhibitor, and combinations thereof. The first surface of the matrix is configured to be applied to the surgical cavity; the device releases the particles through the first surface; the device is also sterilized and provides release of approximately 20% to 100% of the therapeutic agent within 20 minutes of application to the surgical cavity.

Abstract: Methods, compositions, and devices to limit, modulate, insulate, and/or otherwise alter the effects of exogenous physical stimuli on cells are described herein. The cells may be removed from the body, preferably isolated, and treated ex vivo with the composition to limit the effects of physical stimuli on the cells and then returned to the patient. Alternatively, the cells may be treated in vivo. The compositions can be administered a variety of manners, such as systemically, locally or regionally.

Abstract: The present disclosure provides compositions containing ketamine and methods of using those compositions for the treatment of post-traumatic stress disorder. Also provided herein is a pharmaceutical composition that comprises esketamine and a pharmaceutically acceptable carrier, excipient or diluent, for use in treatment of PTSD. In some aspects, the pharmaceutical composition is for intranasal or intravenous administration. In some aspects, the pharmaceutical composition is for use in a method of treating PTSD in a subject. In some aspects, the pharmaceutical composition is for use in a method of treating major depressive disorder in a subject that is co-morbid with the PTSD.

Abstract: Epinephrine formulated in aqueous solvent at a basic pH of about 8.5 remains in solid state. My data show that epinephrine formulated at a pH of about 8.5 is surprisingly resistant to oxidation. I here teach how to formulate solid-state epinephrine in basic solution, and how to use solid-state epinephrine to make pharmaceutical dosage forms.

Abstract: Disclosed herein are topical compositions comprising a quaternary ammonium salt and optionally ammonium chloride and/or stabilized chlorine dioxide. Also disclosed herein are methods of reducing the severity and/or duration of a dermal and or mucosal infection such as herpes or shingles. Also disclosed herein are methods of preventing the spread of a viral infection such as HIV. Also disclosed herein are methods of treating a viral infection such as keratoconjunctivitis.

Abstract: A method of reducing the risk of medication-related overdose, death, or other injury associated with inappropriate consumption of alcohol in conjunction with prescription opioid analgesics, comprising: administering a combination medication having an effective amount of one or more opioid medications, and an effective amount of one or more aldehyde dehydrogenase inhibitors, in order to provide the powerful analgesic effects of the opioid in conjunction with a substance that prevents concomitant alcohol consumption, thereby reducing the risk of alcohol mediated opioid overdose or death. A combination medication, including an effective amount of one or more opioid medications, and an effective amount of one or more aldehyde dehydrogenase inhibitors and a pharmaceutically acceptable carrier.

Abstract: The invention relates to aqueous suspension pharmaceutical compositions of poorly water soluble drugs, wherein said drugs are selected from compounds of formula I wherein R1-R9 are defined herein; processes for preparing these compositions and their use in medicine, especially their use in the treatment of ocular diseases.

Abstract: This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.

Abstract: Treatment of intrahepatic cholestatic diseases by therapy with seladelpar or a salt thereof.

Abstract: In one aspect, the present invention provides a composition of a covalent conjugate of a GABA analog with a drug. In another aspect, the present invention provides methods for treating pain and neurological disorders using the conjugates of GABA analogs.

Abstract: The present invention relates to a high adhesion dermal therapeutic system comprising an adhesive polymeric matrix with a salt of Diclofenac.

Abstract: A composition for enhancing neuroregeneration of the sciatic nerve in a mammal is provided that includes medicinally effective amounts of glycine, glutamine, and phenylalanine. In some embodiments, the glutamine can be L-glutamine and the phenylalanine can be D, L-phenylalanine. A method for treating sciatic pain is also included.

Abstract: Described herein is the surprising discovery that ketone bodies protect cell and tissues from ionizing radiation. Based on this finding, methods of protecting animal tissue and cells from damage caused by radiation exposure are disclosed which include, contacting the tissue with a therapeutically effective amount of an agent including at least one ketone ester, thereby protecting the tissue from radiation damage. Ketone esters can be used to minimize, reduce and/or prevent tissue damage following intentional and accidental radiation exposure, as well as increasing the therapeutic efficacy of radiation therapies by protecting non-target tissue from incidental radiation damage.

Abstract: Disclosed are compositions, devices, and methods to prevent and recover from detrimental effects of alcohol consumption, including significant undesirable symptoms of a hangover consciously felt by the alcohol consumer, as well as those that may not be consciously experienced. The present technology comprehensively targets multiple negative effects of hangovers. In one aspect, a composition includes dihydromyricetin (DHM); and N-acetyl cysteine (NAC). The composition may further include Prickly Pear Extract, Milk Thistle, Ginger Root, Vitamins B, C, and E, electrolytes, and/or sugars.

Abstract: The present invention disclosed a formulation in the form of self-emulsifying drug delivery formulation for improved delivery of tocotrienols comprising a fat-soluble compound, at least one emulsifier, and an oil carrier. The formulation shows an improved bioavailability of tocotrienols.

Abstract: Processes for decreasing expression of a CD274 gene and/or a PD-L1 protein and increasing expression of a PDCD1 gene and/or a PD-1 protein in a subject in need of such expression changes are provided. The processes include administering to the subject a composition including at least 0.5% of cinnamtannin D-1 and/or cinnamtannin B-1. The processes further include decreasing expression of a CD274 gene and/or a PD-L1 protein and increasing expression of a PDCD1 gene and/or a PD-1 protein in the subject by the step of administering at the desired concentration or for the desired time wherein the composition may increase or decrease the relative expression levels of the genes or proteins while simultaneously ameliorating, preventing, or modulating a cardiac event in the subject.

Abstract: Disclosed herein are methods of using daphnoretin to treat, prevent or reduce the incidence of organ transplant rejection and graft-versus-host disease (GVHD). According to embodiments of the present disclosure, daphnoretin is administered to the recipient subject or to the donor organ prior to the transplantation to reduce immune response in the recipient subject against the transplanted organ, or to lower the risk of developing GVHD in the recipient subject.

Abstract: The present invention relates to solid oral formulations comprising a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2?-methyl-1,1?-biphenyl-4-yl)carbonyl]pyrrolidin-3-one-O-methyloxime, and/or an active metabolite thereof, and the use of said formulations in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea and embryo implantation failure due to uterine contractions. The present invention is furthermore related to processes for their preparation.